Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 4.460-4.460 for the period, compared to the consensus EPS estimate of 4.490. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Prestige Consumer Healthcare also updated its FY25 guidance to $4.40 to $4.46 EPS.

Wall Street Analysts Forecast Growth

PBH has been the subject of a number of recent analyst reports. Jefferies Financial Group reaffirmed a "hold" rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a "buy" rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $94.20.

Prestige Consumer Healthcare Stock Up 3.1 %

Shares of PBH traded up $2.43 on Thursday, hitting $80.07. The company's stock had a trading volume of 355,414 shares, compared to its average volume of 247,570. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of 19.58, a P/E/G ratio of 2.08 and a beta of 0.47. The firm's fifty day moving average price is $72.43 and its 200-day moving average price is $69.78. Prestige Consumer Healthcare has a fifty-two week low of $56.61 and a fifty-two week high of $81.25.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm's revenue was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.06 earnings per share. On average, equities research analysts expect that Prestige Consumer Healthcare will post 4.43 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.